STATEMENT OF NEED
Atopic dermatitis is a severe form of eczema pathologically characterized by skin barrier disruption mediated by a type 2 helper T-cell immune response. The incidence of atopic dermatitis is high, estimated to be approximately 15% to 20% in children and 1% to 3% in adults worldwide (Avena-Woods, 2017). In addition to the hallmark clinical symptoms of eczema and intense pruritus, atopic dermatitis is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life (Avena-Woods, 2017). The presence of these effects highlights the importance of understanding disease severity and impact from the patient’s perspective and the need to ensure that disease management is tailored to the needs of the individual patient. In the absence of a cure, atopic dermatitis requires treatment over the lifetime of the patient.
Dermatologists, primary care physicians, physician assistants, nurse practitioners, nurses, and other health care professionals involved in the treatment of adult patients with atopic dermatitis.
Upon completion of this activity, participants should be able to:
Steven R. Feldman, MD, PhD
Professor of Dermatology
Wake Forest Baptist Health
There is no fee to participate in or claim CME/NCPD credit for this activity.
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Steven R. Feldman, MD, PhD, discloses that he has served as a consultant for AbbVie, Advance Medical, Almirall, Alvotech, Amgen, Arena, Bristol Myers Squibb, Caremark, Celgene, Galderma Laboratories, Gerson Lehrman Group, Guidepoint Global, Helsinn, Janssen, Kikaku, LEO, Lilly, Merck, Mylan, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sienna, Sun, Suncare Research, and XenoPort. He has received grant support from AbbVie, Amgen, Celgene, Galderma Laboratories, Janssen, Lilly, Novartis, Pfizer, Regeneron, and Sanofi and served on the speaker's bureau for AbbVie, Amgen, Celgene, Janssen, LEO, Lilly, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, and Sun. He has stocks and has served corporate roles in Medical Quality Enhancement Corporation (majority owner), and Causa Research (founder, stockholder, chief technology officer). Dr. Feldman receives royalties from Informa, UpToDate, and Xlibris.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Incyte.
Aggregate participant data will be shared with commercial supporters of this activity.
Atopic dermatitis is the most common form of eczema, affecting over 9.6 million children and approximately 16.5 million adults in the US. Selma Khenissi, Editorial Assistant at i3 Health and Oncology Data Advisor, recently sat down with Dr. Steven Feldman, Professor of Dermatology at Wake Forest Baptist Health and chair of the continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity Optimizing the Management of Moderate-to-Severe Atopic Dermatitis in Adult Patients, to discuss why patient adherence to treatment is important and the strategies to achieve it.